DNLI on XNAS, Health Care, Denali Therapeutics Inc., job postings
Measures activity, not value. Not investment advice.
News coverage hit 7.0 times its usual week while Denali lost $314.4M and burned $450M in cash over 12 months.
GoodShares up 7.5% over 12 months but down 1.2% in one month
WatchShort interest 9.2% of shares, down 5.0% from two weeks earlier
Written by AI from the data on this page, 21 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Industry
Biological products, (no diagnostic substances) (Health Care)
expected around 25 Feb 2027 (an estimate: a year ago it reported on 26 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $17.8M, net income $70.1M.
31 Dec 2021RevenueNet incomeNet losstallest bar $294.1M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$17.8M
$70.1M
30 Jun 2026
$3.6M
-$127.6M
31 Mar 2026
–
-$128.4M
31 Dec 2025
$0
-$128.5M
30 Sep 2025
$0
-$126.9M
30 Jun 2025
$0
-$124.1M
31 Mar 2025
–
-$133.0M
31 Dec 2024
$0
-$114.8M
30 Sep 2024
$0
-$107.2M
30 Jun 2024
$0
-$99.0M
31 Mar 2024
$0
-$101.8M
31 Dec 2023
–
-$119.5M
30 Sep 2023
$1.3M
-$99.4M
30 Jun 2023
$294.1M
$183.4M
31 Mar 2023
$35.1M
-$109.8M
31 Dec 2022
$10.3M
-$98.7M
30 Sep 2022
$3.6M
-$103.3M
30 Jun 2022
$52.5M
-$58.8M
31 Mar 2022
$42.1M
-$65.2M
31 Dec 2021
$12.5M
-$75.3M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$314.4M
-$498.7M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$1.73
-$2.92
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-33.9%
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
-$450.0M
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$516.2M
$848.2M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$516.2M (net cash)
-$848.2M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$5.78
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
3.2
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider buy/sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$364K
bought $0, sold $364K
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-1.0%
283 13F filers vs 286
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
95%
152.0M shares held by 13F filers (30 Sep 2026) of 160.3M outstanding (28 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
9.2%
14.7M shares sold short (30 Oct 2026) of 160.3M outstanding (28 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
9.9
14.7M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-5.0%
15.5M shares sold short in the report before, 14.7M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
62%
62% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 58%
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$280K
4 quarters
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
15
15 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
7.5×
15 articles in the last 7 days; its usual week has 2.
Unusual now sharp changes in the last 90 days, compared with its own past
Revenue $17.8M
Price $18.45 on 20 Nov 2026, +7.5% over 12 months (12-month range $16.02 to $27.21)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $1.3M in the last 12 months (the 12 months before: -$9.6M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 6 published in the last 12 months, -33% on the 12 months before.Revenue per quarter. Revenue $17.8M in the latest quarter.Capital spending per quarter. Capital spending $1.0M in the latest quarter.Institutional holders (13F filers). 283 13F filers reported holding it in the latest 13F quarter, +24% on a year earlier.Lobbying spend. Lobbying spend: $280K published in the last 12 months, +37% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $12.5M, -96% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $42.1M, +432% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $52.5M, +129% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $3.6M, -33% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $10.3M, -18% on a year earlier; public on 28 Feb 2023
Quarter ended 31 Mar 2023: $35.1M, -17% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $294.1M, +460% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $1.3M, -64% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Mar 2024: $0, -100% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $0, -100% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $0, -100% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $0; public on 28 Feb 2025
Quarter ended 30 Jun 2025: $0; public on 7 Aug 2026
Quarter ended 30 Sep 2025: $0; public on 4 Nov 2026
Quarter ended 31 Dec 2025: $0; public on 27 Feb 2026
Quarter ended 30 Jun 2026: $3.6M; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $17.8M; public on 4 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $3.1M, +155% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $4.0M, +44% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $2.9M, +275% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $6.0M, +223% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $4.8M, +59% on a year earlier; public on 28 Feb 2023
Quarter ended 31 Mar 2023: $2.8M, -31% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $5.8M, +102% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $2.1M, -66% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $2.2M, -54% on a year earlier; public on 29 Feb 2024
Quarter ended 31 Mar 2024: $2.1M, -23% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $4.8M, -18% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $3.9M, +88% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $5.1M, +128% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $5.1M, +136% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $4.3M, -11% on a year earlier; public on 12 Aug 2025
Quarter ended 31 Dec 2025: $1.5M, -70% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $2.5M, -51% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $805K, -81% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $1.0M; public on 4 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 194; public on 14 Feb 2022
31 Mar 2022 report: 177; public on 16 May 2022
30 Jun 2022 report: 176; public on 15 Aug 2022
30 Sep 2022 report: 185; public on 14 Nov 2022
31 Dec 2022 report: 185; public on 14 Feb 2023
31 Mar 2023 report: 190; public on 15 May 2023
30 Jun 2023 report: 187; public on 14 Aug 2023
30 Sep 2023 report: 177; public on 14 Nov 2023
31 Dec 2023 report: 197; public on 14 Feb 2024
31 Mar 2024 report: 200; public on 15 May 2024
30 Jun 2024 report: 189; public on 14 Aug 2024
30 Sep 2024 report: 208; public on 14 Nov 2024
31 Dec 2024 report: 221; public on 14 Feb 2025
31 Mar 2025 report: 214; public on 15 May 2025
30 Jun 2025 report: 220; public on 14 Aug 2025
30 Sep 2025 report: 229; public on 14 Nov 2025
31 Dec 2025 report: 243; public on 17 Feb 2026
31 Mar 2026 report: 259; public on 15 May 2026
30 Jun 2026 report: 286; public on 14 Aug 2026
30 Sep 2026 report: 283; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Apr 2025: $68K published
Quarter from 1 Jul 2025: $68K published
Quarter from 1 Oct 2025: $70K published
Quarter from 1 Jan 2026: $70K published
Quarter from 1 Apr 2026: $70K published
Quarter from 1 Jul 2026: $70K published
Quarter from 1 Oct 2026: $70K published
What is unusual now
Made public in the last 90 days: it reported revenue of $17.8M for the quarter ended 30 Sep 2026, against none in the same quarter last year.
Quarterly revenue change: reported revenue of $17.8M for the quarter ended 30 Sep 2026, against none in the same quarter last year Public on 5 Nov 2026.
Reported lobbying spend: $70K in Q3 2026, $70K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
1 Jan 2025
New
Manatt, Phelps, And Phillipsfor Denali Therapeutics
Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Medicaid policies that impact access to innovative treatments for pediatric rare diseases; rare disease drug developmentHealth issues
Two or more unrelated kinds of records unusual within 30 days
29 Apr 2025confirmed
Confirmed across sources Lobbying and Short interest and volume
Denali Therapeutics(DNLI): registered for federal lobbying for the first time in our data (Manatt, Phelps, And Phillips), while it had 13.0M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year. Two unrelated kinds of activity within 15 days.
Lobbying: First lobbying registration, became public on 14 Apr 2025
Short interest and volume: Short interest spike, became public on 26 Apr 2025
The 15 Apr 2025 report against the 24 reports before it.
this reportearliernormal: 8.2MSee the evidence (2 changes)
Lobbying: First lobbying registration became public on 14 Apr 2025
Denali Therapeutics registered for federal lobbying for the first time in our data (Manatt, Phelps, And Phillips).
"First" means first in our data: it fires only when the source's history began at least 365 days earlier.
Short interest and volume: Short interest spike became public on 26 Apr 2025
Denali Therapeutics had 13.0M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year.
This period
13.0M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
8.2M
Typical spread (median absolute deviation)
765K
How far from its usual level
+4.3
Same report last year
9.6M
History used
2,664 days
the 15 Apr 2025 report24 earlier reportsnormal: 8.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
5 Nov 2026Financials change
reported revenue of $17.8M for the quarter ended 30 Sep 2026, against none in the same quarter last year.
See the evidence
This period
$17.8M (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
$0
Typical spread (median absolute deviation)
$0
How far from its usual level
+17.8
Same quarter last year
$0
History used
3,379 days
the quarter ended 30 Sep 20268 earlier quartersnormal: $0
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
saw 41 13F filers open a new position in the quarter ended 31 Dec 2025, 1.4× the same quarter last year.
Same quarter last year: 29; its normal quarter is 30.
See the evidence
This period
41 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
30
Typical spread (median absolute deviation)
1.5
How far from its usual level
+3.7
Same quarter last year
29
History used
2,922 days
the quarter ended 31 Dec 20258 earlier quartersnormal: 30
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
saw 42 13F filers open a new position in the quarter ended 30 Jun 2025, 1.6× the same quarter last year.
Same quarter last year: 26; its normal quarter is 28.5.
See the evidence
This period
42 (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
28.5
Typical spread (median absolute deviation)
2
How far from its usual level
+4.5
Same quarter last year
26
History used
2,738 days
the quarter ended 30 Jun 20258 earlier quartersnormal: 28.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 12.2M shares sold short in the 30 May 2025 report, 1.3× the same report last year.
Same report last year: 9.3M; its normal report is 8.2M.
See the evidence
This period
12.2M (the 30 May 2025 report)
Normal report (median of 24 earlier)
8.2M
Typical spread (median absolute deviation)
765K
How far from its usual level
+3.6
Same report last year
9.3M
History used
2,709 days
the 30 May 2025 report24 earlier reportsnormal: 8.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
registered for federal lobbying for the first time in our data (Manatt, Phelps, And Phillips), while it had 13.0M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year. Two unrelated kinds of activity within 15 days.
See the evidence (2 changes)
Lobbying: First lobbying registration became public on 14 Apr 2025
Denali Therapeutics registered for federal lobbying for the first time in our data (Manatt, Phelps, And Phillips).
"First" means first in our data: it fires only when the source's history began at least 365 days earlier.
Short interest and volume: Short interest spike became public on 26 Apr 2025
Denali Therapeutics had 13.0M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year.
This period
13.0M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
8.2M
Typical spread (median absolute deviation)
765K
How far from its usual level
+4.3
Same report last year
9.6M
History used
2,664 days
the 15 Apr 2025 report24 earlier reportsnormal: 8.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
26 Apr 2025Short interest and volume change
had 13.0M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year.
Same report last year: 9.6M; its normal report is 8.2M.
See the evidence
This period
13.0M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
8.2M
Typical spread (median absolute deviation)
765K
How far from its usual level
+4.3
Same report last year
9.6M
History used
2,664 days
the 15 Apr 2025 report24 earlier reportsnormal: 8.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $294.1M for the quarter ended 30 Jun 2023, 5.6× the same quarter last year.
Same quarter last year: $52.5M; its normal quarter is $16.6M.
See the evidence
This period
$294.1M (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
$16.6M
Typical spread (median absolute deviation)
$13.9M
How far from its usual level
+13.5
Same quarter last year
$52.5M
History used
2,191 days
the quarter ended 30 Jun 20238 earlier quartersnormal: $16.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $52.5M for the quarter ended 30 Jun 2022, 2.3× the same quarter last year.
Same quarter last year: $22.9M; its normal quarter is $6.9M.
See the evidence
This period
$52.5M (the quarter ended 30 Jun 2022)
Normal quarter (median of 8 earlier)
$6.9M
Typical spread (median absolute deviation)
$2.4M
How far from its usual level
+13.0
Same quarter last year
$22.9M
History used
1,826 days
the quarter ended 30 Jun 20228 earlier quartersnormal: $6.9M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 7.8M shares sold short in the 15 Jun 2022 report, 1.5× the same report last year.
Same report last year: 5.4M; its normal report is 5.7M.
See the evidence
This period
7.8M (the 15 Jun 2022 report)
Normal report (median of 24 earlier)
5.7M
Typical spread (median absolute deviation)
346K
How far from its usual level
+3.6
Same report last year
5.4M
History used
1,629 days
the 15 Jun 2022 report24 earlier reportsnormal: 5.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.8M shares sold short in the 31 May 2022 report, 1.4× the same report last year.
Same report last year: 5.7M; its normal report is 5.7M.
See the evidence
This period
7.8M (the 31 May 2022 report)
Normal report (median of 24 earlier)
5.7M
Typical spread (median absolute deviation)
319K
How far from its usual level
+3.6
Same report last year
5.7M
History used
1,614 days
the 31 May 2022 report24 earlier reportsnormal: 5.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $42.1M for the quarter ended 31 Mar 2022, 5.3× the same quarter last year.
Same quarter last year: $7.9M; its normal quarter is $6.9M.
See the evidence
This period
$42.1M (the quarter ended 31 Mar 2022)
Normal quarter (median of 8 earlier)
$6.9M
Typical spread (median absolute deviation)
$2.4M
How far from its usual level
+10.1
Same quarter last year
$7.9M
History used
1,735 days
the quarter ended 31 Mar 20228 earlier quartersnormal: $6.9M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $22.9M for the quarter ended 30 Jun 2021, 3.9× the same quarter last year.
Same quarter last year: $5.8M; its normal quarter is $5.2M.
See the evidence
This period
$22.9M (the quarter ended 30 Jun 2021)
Normal quarter (median of 8 earlier)
$5.2M
Typical spread (median absolute deviation)
$1.4M
How far from its usual level
+8.7
Same quarter last year
$5.8M
History used
1,461 days
the quarter ended 30 Jun 20218 earlier quartersnormal: $5.2M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
saw 51 13F filers open a new position in the quarter ended 31 Dec 2020, 4.6× the same quarter last year.
Same quarter last year: 11; its normal quarter is 24.5.
See the evidence
This period
51 (the quarter ended 31 Dec 2020)
Normal quarter (median of 8 earlier)
24.5
Typical spread (median absolute deviation)
4
How far from its usual level
+4.5
Same quarter last year
11
History used
1,096 days
the quarter ended 31 Dec 20208 earlier quartersnormal: 24.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
reported revenue of $13.6M for the quarter ended 30 Sep 2019, 11× the same quarter last year.
Same quarter last year: $1.2M; its normal quarter is $1.4M.
See the evidence
This period
$13.6M (the quarter ended 30 Sep 2019)
Normal quarter (median of 8 earlier)
$1.4M
Typical spread (median absolute deviation)
$1.4M
How far from its usual level
+5.8
Same quarter last year
$1.2M
History used
822 days
the quarter ended 30 Sep 20198 earlier quartersnormal: $1.4M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
spent $10.3M on capital projects in the quarter ended 30 Jun 2019, 18× the same quarter last year.
Same quarter last year: $572K; its normal quarter is $710K.
See the evidence
This period
$10.3M (the quarter ended 30 Jun 2019)
Normal quarter (median of 8 earlier)
$710K
Typical spread (median absolute deviation)
$258K
How far from its usual level
+9.6
Same quarter last year
$572K
History used
821 days
the quarter ended 30 Jun 20198 earlier quartersnormal: $710K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
reported revenue of $125.7M for the quarter ended 31 Dec 2018, against none in the same quarter last year.
See the evidence
This period
$125.7M (the quarter ended 31 Dec 2018)
Normal quarter (median of 6 earlier)
$320K
Typical spread (median absolute deviation)
$320K
How far from its usual level
+125.4
Same quarter last year
$0
History used
549 days
the quarter ended 31 Dec 20186 earlier quartersnormal: $320K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Not listed: 348 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it